1. Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
- Author
-
Jiaye Liu, Shaohui Qiu, Jingjing Lu, Bingyu Yan, Yi Feng, Li Li, Guomin Zhang, Fuzhen Wang, Peng He, Xin Fang, Zhongyu Hu, Xiaofeng Liang, Aiqiang Xu, Li Zhang, Liu, Jiaye, Qiu, Shaohui, Lu, Jingjing, Yan, Bingyu, Feng, Yi, and Li, Li
- Subjects
CHRONIC hepatitis C ,HEPATITIS B vaccines ,PHYSIOLOGICAL effects of cytokines ,IMMUNOGLOBULINS ,IMMUNOREGULATION ,PUBLIC health ,VACCINES ,THERAPEUTICS ,HEPATITIS B prevention ,CELLULAR immunity ,CLINICAL trials ,COMPARATIVE studies ,CYTOKINES ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,VIRAL antibodies ,VIRAL antigens ,LOGISTIC regression analysis ,EVALUATION research ,CASE-control method - Abstract
Background: Hepatitis B vaccine is an effective measure to prevent hepatitis B virus infection. Whether chronic hepatitis C virus (HCV) infection decreases humoral and cell-mediated immunity responses to hepatitis B vaccination is still controversial.Methods: Patients with chronic HCV infection who were not in treatment and healthy controls, matched at a 1:2 ratio for community, sex, and age (within 5 years), were identified from a community-based screening. All participants received 3 doses of hepatitis B vaccine. Antibody to hepatitis B surface antigen was tested 1 month after the third vaccine dose and was compared between 2 groups. Spot-forming cells (SFCs) of interferon γ and interleukin 2, 4, 5, and 6 were counted by means of enzyme-linked immunospot, and SFC counts were compared between the 2 groups.Results: The rates of nonresponse and low, normal, and high response were 3.80%, 10.13%, 45.57%, and 40.50% respectively, in the HCV group, and the corresponding rates in the healthy control group were 1.26%, 10.13%, 39.24%, and 49.37% (all P > .05). There were no significant differences in SFC counts between the 2 groups for interferon γ or interleukin 2, 4, or 5 (all P > .05).Conclusions: This study provided preliminary evidence of the good immunogenicity and safety of hepatitis B vaccination among patients in China with chronic hepatitis C who are not in treatment.Clinical Trials Registration: NCT 02898922. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF